|Richard Whittington, Gregory A Broderick, Peter Arger, et. al.|
|Abramson Cancer Center of the University of Pennsylvania|
| Last Modified: November 1, 2001
Reviewers: Li Liu, MD
BackgroundThe rising incidence of and mortality from prostate cancer has generated great interest in improving the results of current methods of treatment. The use of total androgen deprivation for treatment of prostate cancer, including therapy of early localized disease, has become more popular over the last decade or two. Quantitative measurement of the change in volume of the prostate after neoaduvant androgen deprivation remains lacking.
Methods69 patients undergoing prostate brachytherapy for clinical stage T1c-T2b adenocarcinoma of the prostate were treated with at least 3 months of androgen deprivation therapy. Prostate volume was measured using ultrasound and/or CT scans at diagnosis, before the implant, and 11 to 13 days following the implant.
DiscussionNeoadjuvant hormonal therapy resulted in a median reduction in prostate volume of 33%. This reduction may facilitate the use of brachytherapy implants in the patients who would otherwise not to be ideal candidates due to the large volume of the prostate gland at diagnosis.